![]() The study brings a perfect bridging between qualitative and statistical data of Specialty Generics Market. Between 20, this market is estimated to register a CAGR of 8.7%. ![]() In 2022, the global Specialty Generics market was valued at USD 74.3 billion and is expected to reach around USD 167.6 billion in 2032. The worldwide market strategies undertaken, with respect to the current and future scenario of the industry, have also been listed in the study. The Specialty Generics market report presents data and information on the development of the investment structure, technological improvements, market trends and developments, capabilities, and comprehensive information on the key players of the Specialty Generics market. This survey report covers the major market insights and industry approach towards upcoming years. To read this article on click here.The latest research report provides a complete assessment of the Specialty Generics market for the forecast year 2023-2033, which is beneficial for companies regardless of their size and revenue. (MRNA) : Free Stock Analysis ReportĮmergent Biosolutions Inc. Click to get this free reportĮndo International plc (ENDP) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Moderna topped earnings estimates in two of the last four quarters and missed the mark on the other two, delivering a negative surprise of 35.8%, on average. ![]() Moderna MRNA has an Earnings ESP of +1.90% and a Zacks Rank #3 at present.Įarnings per share estimates of Moderna for 2022 have increased $1 in the past 30 days. VIR topped earnings estimates in two of the last four quarters and missed the mark on the other two, delivering a surprise of 13%, on average.Įmergent Biosolutions EBS has an Earnings ESP of +18.40% and a Zacks Rank #3.Įarnings per share estimates of EBS for 2022 have increased to $3.12 from $3.09 in the past seven days. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Įarnings per share estimates of Vir Biotechnology for 2022 have increased $6.52. Vir Biotechnology VIR has an Earnings ESP of +32.05% and a Zacks Rank #3. Here are some health care stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. Endo International plc Price, Consensus and EPS SurpriseĮndo International plc price-consensus-eps-surprise-chart | Endo International plc Quote Stocks to Consider Zacks Rank: It currently carries a Zacks Rank #5 (Strong Sell). Hence, the total revenues are expected to have recorded sequential growth.Įarnings ESP: Earnings ESP of Endo is +5.71%, as the Zacks Consensus Estimate stands at 70 cents and the Most Accurate Estimate is 74 cents. Revenues for 2021 are projected to be $2.90-$2.94 billion compared with the earlier estimated range of $2.73-$2.79 billion. International Pharmaceuticals revenues declined in the previous quarter, and the same trend is likely to have prevailed in the fourth quarter.Ĭoncurrent with the third-quarter results, Endo upped its annual revenue projections. The fourth quarter is likely to have witnessed similar or higher levels of growth. Generic Pharmaceuticals reported 29% growth in the third quarter revenues due to additional revenues from the 2021 product launches. This trend is expected to have continued in the fourth quarter. Sterile Injectables’ revenues jumped 37% year over year in the previous quarter due to increased Vasostrict revenues. However, Established Products revenues decreased 17% in the third quarter, and revenues from this franchise might have declined this time as well. Sales of Xiaflex increased 20% in the previous quarter, and the drug is likely to have recorded sequential growth in the fourth quarter. Within the segment, Specialty Products revenues increased 16% in the prior quarter. Image Source: Zacks Investment Research Factors at PlayĮndo has four reportable business segments - Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables and International Pharmaceuticals.īranded Pharmaceuticals’ revenues were up 3% in the third quarter, and similar levels of growth might have been registered in the fourth quarter.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |